Metastatic ccRCC are pharmacologically managed, targeted therapy utilizing tyrosine kinase inhibitors (TKIs), anti-VEGF antibodies, mammalian target of rapamycin (mTOR), and/or immune checkpoint inhibitors are widely used in first and second line treatments, suggesting that treatment strategy is crucial for ccRCC treatment (2). This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.